Clinical trials reveal promising alternatives to high-toxicity tuberculosis drug

The drugs, sutezolid and delpazolid, have demonstrated strong antimicrobial activity and a notably better safety profile compared to linezolid, with the potential to replace this current cornerstone in the treatment of drug-resistant TB.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup